OTC kids’ cough/cold hearing update
This article was originally published in The Tan Sheet
Executive Summary
Members of the public wishing to register for the public hearing to discuss OTC cough/cold drugs for pediatric use should contact FDA's Faith Dugan directly at [email protected], rather than go through the 2www.regulations.gov Web site as previously instructed, according to a Federal Register notice slated for publication Sept. 2. FDA provided the updated information about the public hearing to clarify and simplify electronic registration for meeting participants, the agency says
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.